Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?

Published

on

Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?
Shares of pharma companies rallied up to 7% on Wednesday as strong earnings, a weakening rupee, and other supportive factors lifted investor sentiment, even as benchmark indices Sensex and Nifty traded in the red.

After opening lower, the Nifty Pharma index reversed losses and climbed nearly 1% to cross the 25,000 mark. The sectoral index also touched a fresh 52-week high of 25,043 during early trade before trimming some gains.

The Indian currency fell to 96.96 per dollar, breaching its all-time ‌low of 96.6150 ⁠hit ⁠in the previous session. The currency is down 6% since the Iran war began in late February. A falling rupee is typically considered a positive for the export-heavy pharma sector.

Top pharma gainers today

Zydus Lifesciences shares were the top gainers on the index, jumping over 7% to hit a fresh 52-week high of Rs 1,091 apiece on NSE after the pharma company reported a 9% year-on-year (YoY) rise in consolidated net profit to Rs 1,272.5 crore for the January-March quarter of FY26. Revenue from operations, meanwhile, rose more than 16% YoY to Rs 7,587 crore during the quarter under review.Along with the Q4 results, Zydus Lifesciences announced its biggest-ever share buyback worth Rs 1,100 crore via the tender route at a buyback price of Rs 1,150 per share, offering nearly a 13% premium over the stock’s previous closing price. Its board has also recommended a final dividend of Re 1 per share (100%) on a face value of Re 1 each, subject to shareholders’ approval at the company’s Annual General Meeting scheduled for August 11.

Advertisement

Mankind Pharma shares followed, surging over 3%. This comes after the company reported a 32% YoY rise in consolidated net profit to Rs 554 crore for the fourth quarter of the financial year 2026, from Rs 421 crore in the corresponding quarter of the previous financial year. The firm’s revenue from operations rose 12% YoY to Rs 3,443 crore during the quarter under review.
Laurus Labs, Aurobindo Pharma, and Biocon shares gained around 1% each, while those of Lupin, Sun Pharma, Cipla, Torrent Pharma, and Divi’s Laboratories were trading in the green with marginal gains, as seen at 11 am. Bucking the trend, however, Ajanta Pharma, Piramal Pharma, Gland Pharma, Dr Reddy’s Labs, Abbot India, Glenmark, Alkem Labs, and IPCA Labs shares fell up to 1%.

What lies ahead?

Nifty Pharma’s technical structure remains constructive after the index touched a fresh 52-week high today, according to Harshal Dasani, Business Head at INVasset PMS, who said that this is significant as it has come at a time when the broader market is still dealing with global risk-off pressure, currency weakness, and uneven earnings delivery. The relative strength in pharma counters suggests capital is rotating into sectors with better earnings visibility, not merely chasing momentum, he added.“The index has been forming a clear higher-high, higher-low pattern, and the latest breakout keeps the medium-term trend in favour of buyers as long as it holds above the recent breakout zone. The immediate support now sits around 24,700 to 24,800, while a stronger cushion is visible near 24,400. A close below that band would weaken the breakout and indicate profit-booking rather than trend continuation,” according to Dasani.

The risk-reward remains favourable, but the entry point is no longer fresh after a sharp move, the analyst said. “The cleaner setup would come on controlled pullbacks rather than vertical rallies. The key confirmation from here is breadth. If participation remains broad across large pharma, domestic formulations and speciality businesses, the breakout could extend. If leadership narrows, the index may pause before attempting the next leg,” he added.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Vessel forced out of New York ship parade over ’politically charged’ banners

Published

on

Vessel forced out of New York ship parade over ’politically charged’ banners


Vessel forced out of New York ship parade over ’politically charged’ banners

Continue Reading

Business

Core Scientific: A Bullish Bet On AI Power Scarcity

Published

on

Core Scientific: A Bullish Bet On AI Power Scarcity

Core Scientific: A Bullish Bet On AI Power Scarcity

Continue Reading

Business

Politics And The Markets 07/05/26

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This is the forum for daily political discussion on Seeking Alpha. A new version is published every market day.

Please don’t leave political comments on other articles or posts on the site.

The comments below are not regulated with the same rigor as the rest of the site, and this is an ‘enter at your own risk’ area as discussion can get very heated. If you can’t stand the heat… you know what they say…

More on Today’s Markets:

Advertisement

Moderation Guidelines:

We remove comments under the following categories:

  • Personal attacks on another user account
  • Anti-Vaxxer or covid related misinformation
  • Stereotyping, prejudiced or racist language about individuals or the topic under discussion.
  • Inciting violence messages, encouraging hate groups and political violence.

Regardless of which side of the political divide you find yourself, please be courteous and don’t direct abuse at other users.

For any issue with regards to comments please email us at : moderation@seekingalpha.com.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Linde: Space Growth Prospects Already At Orbit

Published

on

SpaceX: What Does History Tell Us About Investing In The Biggest IPOs? I Am Cautiously Optimistic

Linde: Space Growth Prospects Already At Orbit

Continue Reading

Business

WhiteFiber: A Small-Cap Way To Own The AI Power Bottleneck

Published

on

Cipher Digital: Taking Advantage Of An Expensive, Volatile Stock Through Options (NASDAQ:CIFR)

WhiteFiber: A Small-Cap Way To Own The AI Power Bottleneck

Continue Reading

Business

India regains favor as investors seek shelter from AI-driven market swings

Published

on


India regains favor as investors seek shelter from AI-driven market swings

Continue Reading

Business

VFH: Financials Staging A Strong Rally Ahead Of The Q2 Earnings Season (NYSEARCA:VFH)

Published

on

VFH: Financials Staging A Strong Rally Ahead Of The Q2 Earnings Season (NYSEARCA:VFH)

This article was written by

Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrative to financial data. Working with teams that include senior editors, investment strategists, marketing managers, data analysts, and executives, I contribute ideas to help make content relevant, accessible, and measurable. Having expertise in thematic investing, market events, client education, and compelling investment outlooks, I relate to everyday investors in a pithy way. I enjoy analyzing stock market sectors, ETFs, economic data, and broad market conditions, then producing snackable content for various audiences. Macro drivers of asset classes such as stocks, bonds, commodities, currencies, and crypto excite me. My thing is communicating finance with an educational and creative style. I also believe in producing evidence-based narratives using empirical data to drive home points. Charts are one of the many tools I leverage to tell a story in a simple but engaging way. I focus on SEO and specific style guides when appropriate.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Australia to sign Fiji security pact, advance India uranium export deal

Published

on


Australia to sign Fiji security pact, advance India uranium export deal

Continue Reading

Business

Broadcom: This Is Just The Start Of A New Leg Up

Published

on

Broadcom: This Is Just The Start Of A New Leg Up

Broadcom: This Is Just The Start Of A New Leg Up

Continue Reading

Business

BDC Weekly Review: Q2 Private BDC Returns Bounce Back

Published

on

Whale's Insight: A Macro-Driven Market With No Safe Haven, And No End To Volatility

BDC Weekly Review: Q2 Private BDC Returns Bounce Back

Continue Reading

Trending

Copyright © 2025